Research Using the MOATT
A Structured Nursing Intervention at Dana-Farber Cancer Institute
Jean Boucher and colleagues published the results of a study designed to evaluate a nurse-led intervention using the MOATT with the goals of increasing patient knowledge and adherence to therapy. This was a longitudinal, descriptive, feasibility study conducted in an ambulatory thoracic oncology disease center at the Dana-Farber Cancer Institute in Boston, Massachusetts. Thirty adult patients with lung cancer, who were being treated with the oral agent erlotinib, participated in the study (with 27 completing).
In October 2008, the European Medicines Agency recommended the suspension of Acomplia after the Committee for Medicinal Products for Human Use (CHMP) had determined that the risks of Acomplia outweighed its benefits due to the risk of serious psychiatric problems, including suicide.  In November 2008 an advisory committee in Brazil recommended suspension as well, and that month Sanofi-Aventis suspended sale of the drug worldwide.  The EMA approval was withdrawn in January 2009.   In 2009 India prohibited the manufacture and sale of the drug.